Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 13/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5333247 | 0.77 | LTA4H (0.61) | LTA4HPOLB | |
| SCHEMBL5312495 | 0.74 | LTA4H (0.74) | LTA4H | |
| SCHEMBL5315163 | 0.71 | LTA4H (0.69) | LTA4HPOLBNPY5R | |
| SCHEMBL5662113 | 0.71 | LTA4H (1.00) | LTA4H | |
| SCHEMBL8843364 | 0.71 | TLR2 (0.50) | — | |
| SCHEMBL14043916 | 0.71 | FFAR1 (0.70) | LTA4HCACNA1BPOLBSRD5A2 | |
| SCHEMBL8843370 | 0.70 | TLR2 (0.49) | — | |
| SCHEMBL5317924 | 0.69 | LTA4H (1.00) | LTA4H | |
| SCHEMBL7399665 | 0.69 | KCNT1 (0.49) | LTA4HSRD5A2 | |
| SCHEMBL7397721 | 0.69 | KCNT1 (0.49) | LTA4HSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | claimed |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885CACNA1B 1706/4885SMN1; SMN2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.